文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

巴雷特食管异型增生和肿瘤进展的预测因素。

Predictors of dysplastic and neoplastic progression of Barrett’s esophagus.

机构信息

From the Department of General Surgery, McGill University Health Centre, Montreal, Que. (Alnasser); the Department of Epidemiology and Biostatistics – Cancer Epidemiology, McGill University, Montreal, Que. (Agnihotram, Franco); and the Ringgold Standard Institution – Gastroenterology, McGill University Health Centre, Montréal, Que. (Martel, Mayrand, Ferri).

出版信息

Can J Surg. 2019 Apr 1;62(2):93-99. doi: 10.1503/cjs.008716.


DOI:10.1503/cjs.008716
PMID:30907564
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6440887/
Abstract

BACKGROUND: It is unknown why some cases of Barrett’s esophagus progress to invasive malignant disease rapidly while others do so more slowly or not at all. The aim of this study was to identify demographic and endoscopic factors that predict dysplastic and neoplastic progression in patients with Barrett’s esophagus. METHODS: Patients with Barrett’s esophagus who were assessed in 2000–2010 were assessed for inclusion in this retrospective study. Demographic and endoscopic variables were collected from an endoscopy database and the medical chart. Dysplastic and neoplastic progression was examined by time-to-event analysis. We used Cox proportional hazard regression modelling and generalized estimating equation methods to identify variables that were most predictive of neoplastic progression. RESULTS: A total of 518 patients had Barrett’s esophagus confirmed by endoscopy and pathology and at least 2 surveillance visits. Longer Barrett’s esophagus segment (≥ 3 cm) (odds ratio [OR] 1.2, 95% confidence interval [CI] 1.1–1.3) and increased age (≥ 60 yr) (OR 3.5, 95% CI 1.7–7.4) were independent predictors of progression from nondysplasia to dysplastic or neoplastic grades. Presence of mucosal irregularities (OR 8.6, 95% CI 2.4–30.4) and increased age (OR 5.1, 95% CI 1.6–16.6) were independent predictors of progression from nondysplasia to high-grade dysplasia or adenocarcinoma. CONCLUSION: Increased age, longer Barrett’s segment and presence of mucosal irregularities were associated with increased risk of dysplastic and neoplastic progression. In addition to dysplasia, these factors may help stratify patients according to risk of neoplastic progression and be used to individualize surveillance. More prospective studies with larger samples are required to validate these results.

摘要

背景:目前尚不清楚为什么有些巴雷特食管病例会迅速进展为侵袭性恶性疾病,而有些则进展缓慢或根本不会进展。本研究旨在确定预测巴雷特食管患者发生异型增生和肿瘤进展的人口统计学和内镜因素。

方法:对 2000 年至 2010 年进行评估的巴雷特食管患者进行了回顾性研究。从内镜数据库和病历中收集了人口统计学和内镜变量。通过生存时间分析来评估异型增生和肿瘤进展。我们使用 Cox 比例风险回归模型和广义估计方程方法来确定最能预测肿瘤进展的变量。

结果:共有 518 例患者经内镜和病理检查证实存在巴雷特食管,并至少进行了 2 次监测。较长的巴雷特食管段(≥3cm)(比值比[OR]1.2,95%置信区间[CI]1.1-1.3)和年龄较大(≥60 岁)(OR 3.5,95%CI 1.7-7.4)是从非异型增生进展为异型增生或肿瘤级别的独立预测因素。黏膜不规则(OR 8.6,95%CI 2.4-30.4)和年龄较大(OR 5.1,95%CI 1.6-16.6)是从非异型增生进展为高级别异型增生或腺癌的独立预测因素。

结论:年龄较大、巴雷特食管段较长和黏膜不规则与异型增生和肿瘤进展的风险增加相关。除了异型增生,这些因素可能有助于根据肿瘤进展的风险对患者进行分层,并用于个体化监测。需要进行更多的前瞻性研究,以验证这些结果。

相似文献

[1]
Predictors of dysplastic and neoplastic progression of Barrett’s esophagus.

Can J Surg. 2019-4-1

[2]
Does Risk of Progression from Barrett's Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies?

Dig Dis Sci. 2021-6

[3]
Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.

Am J Gastroenterol. 1999-12

[4]
The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus.

Am J Gastroenterol. 1998-4

[5]
Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.

Gastroenterol Clin North Am. 2015-6

[6]
Efficacy of Cryotherapy as a Primary Endoscopic Ablation Modality for Dysplastic Barrett's Esophagus and Early Esophageal Neoplasia: A Systematic Review and Meta-Analysis.

Cancer Control. 2020

[7]
Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.

Am J Gastroenterol. 1997-11

[8]
Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study.

Lancet Gastroenterol Hepatol. 2016-11-11

[9]
The diagnosis and management of Barrett's esophagus.

Adv Surg. 1999

[10]
The Present Status and Future of Barrett's Esophageal Adenocarcinoma in Japan.

Digestion. 2018-11-27

引用本文的文献

[1]
Navigating Endoscopic Surveillance and Management of Barrett's Esophagus in Elderly Patients: Balancing the Risks and Benefits.

Curr Gastroenterol Rep. 2025-6-9

[2]
Extrachromosomal DNA in the cancerous transformation of Barrett's oesophagus.

Nature. 2023-4

[3]
Magnitude and Time-Trend Analysis of Postendoscopy Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis.

Clin Gastroenterol Hepatol. 2022-2

[4]
Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma: Implications for Screening and Surveillance.

Gastrointest Endosc Clin N Am. 2021-1

[5]
Clinical and pathological predictors of failure of endoscopic therapy for Barrett's related high-grade dysplasia and early esophageal adenocarcinoma.

Surg Endosc. 2021-10

本文引用的文献

[1]
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus.

Gut. 2013-10-28

[2]
Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.

Am J Gastroenterol. 2011-5-17

[3]
Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus.

Am J Gastroenterol. 2008-3

[4]
Barrett's columnar-lined oesophagus: demographic and lifestyle associations and adenocarcinoma risk.

Dig Dis Sci. 2008-5

[5]
French Society of Digestive Endoscopy SFED guideline: monitoring of patients with Barrett's esophagus.

Endoscopy. 2007-9

[6]
The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.

Am J Gastroenterol. 2006-8

[7]
Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus.

Am J Gastroenterol. 2006-7

[8]
Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.

Health Technol Assess. 2006-3

[9]
Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial.

Gastrointest Endosc. 2005-10

[10]
Barrett's oesophagus is characterized by a predominantly humoral inflammatory response.

J Pathol. 2005-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索